The use of SPF 100+ sunscreen either delayed or reduced the occurrence of erythema and sunburn when compared with SPF 50+ when used in beach conditions.
This phase 2 serlopitant study is the first randomized clinical trial for EB-related pruritus demonstrating safety and potential itch reduction.
The guideline explains the precautions that should be taken when treating patients with epidermolysis bullosa, as well as recommendations for podiatry treatment.
At Week 8 post-treatment, 92% of the burn sites treated with RECELL System achieved complete healing vs 85% of sites treated with standard-of-care, demonstrating non-inferiority.
The prevalence of sunburn was 34.2% in 2015, and sunburn prevalence was higher in non-Hispanic whites, younger age groups, and those with sun-sensitive skin.
Members of the International Bullous Disease Group convened to update diagnostic criteria for epidermolysis bullosa acquisita.
Autologous platelet-rich plasma is safe and effective for patients with chronic venous leg ulcers, with highly significant improvement in ulcer size.